EUVIMEDEUVIMED entdecken
Scoping ReviewOpen Access · CC BY-NC-ND 4.0

Pharmacological treatment for mental health illnesses in adults receiving dialysis: A scoping review

Jenny Wichart, Peter Yoeun, Tracy Chin, Christopher Evernden, Charlotte Berendonk, Jodi Kerr, Alexandra Birchall, Belinda Boschee, Kimberly Defoe, Jasleen Dhaliwal, Tasia KarisAllen, Megan Kennedy und 3 weitere

Fundamental & Clinical Pharmacology · 2024-10 · 38 (5) · 862-882

DOI: 10.1111/fcp.13022 ↗

Kurz gefasst

Scoping Review in der Zeitschrift Fundamental & Clinical Pharmacology, online erschienen am 15.06.2024. Verfasst von Jenny Wichart und 14 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacy Services, Alberta Health Services, Calgary, Alberta, Canada. Hauptthemen laut MEDLINE: Mental Disorders, Renal Dialysis. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 101 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Kidney Foundation of Canada.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pharmacologic management of mental health illnesses in patients receiving dialysis is complex and lacking data.

Objective

Our objective was to synthesize published data for the treatment of depression, bipolar and related disorders, schizophrenia or psychotic disorders, and anxiety disorders in adults receiving hemodialysis or peritoneal dialysis.

Methods

We undertook a scoping review, searching the following databases: Medline, Embase, CINAHL, PsycINFO, Cochrane Library, Scopus, and Web of Science. Data on patients who received only short‐term dialysis, a kidney transplant, or non‐pharmacologic treatments were excluded.

Results

Seventy‐three articles were included: 41 focused on depression, 16 on bipolar disorder, 13 on schizophrenia and psychotic disorders, 1 on anxiety disorders, and 2 addressing multiple mental health illnesses. The majority of depression studies reported on selective serotonin reuptake inhibitors (SSRIs) as a treatment. Sertraline had the most supporting data with use of doses from 25 to 200 mg daily. Among the remaining SSRIs, escitalopram, citalopram, and fluoxetine were studied in controlled trials, whereas paroxetine and fluvoxamine were described in smaller reports and observational trials. There are limited published data on other classes of antidepressants and on pharmacological management of anxiety. Data on treatment for patients with bipolar disorder or schizophrenia and related disorders are limited to case reports.

Conclusion

Over half of the studies included were case reports, thus limiting conclusions. More robust data are required to establish effect sizes of pharmacological treatments prior to providing specific recommendations for their use in treating mental health illnesses in patients receiving dialysis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mental DisordersRenal DialysisAdultHumansAntidepressive AgentsSelective Serotonin Reuptake Inhibitors

Stichwörter der Autor:innen

dialysismedication therapy managementmental healthscoping review

Substanzen

Antidepressive AgentsSelective Serotonin Reuptake Inhibitors

Autor:innen und Institutionen

  • Pharmacy Services, Alberta Health Services, Calgary, Alberta, Canada.
  • Pharmacy Services, Alberta Health Services, Royal Alexandra Hospital, Edmonton, Alberta, Canada.
  • Pharmacy Services, Alberta Health Services, South Health Campus, Calgary, Alberta, Canada.
  • Faculty of Nursing, University of Alberta, Edmonton Clinic Health Academy, Edmonton, Alberta, Canada.
  • Pharmacy Services, Medicine Hat Regional Hospital, Medicine Hat, Alberta, Canada.
  • DTC OR/PACU, Alberta Health Services, Royal Alexandra Hospital, Edmonton, Alberta, Canada.

ORCID-Profile: Kara Schick-Makaroff

Förderung

  • Kidney Foundation of Canada

Zitieren

APA

Wichart, J., Yoeun, P., Chin, T., Evernden, C., Berendonk, C., Kerr, J., Birchall, A., Boschee, B., Defoe, K., Dhaliwal, J., KarisAllen, T., Kennedy, M., McDonald, A., Mierzejewski, M. K., & Schick-Makaroff, K. (2024). Pharmacological treatment for mental health illnesses in adults receiving dialysis: A scoping review. Fundamental & Clinical Pharmacology, 38(5), 862-882. https://doi.org/10.1111/fcp.13022

Vancouver

Wichart J, Yoeun P, Chin T, Evernden C, Berendonk C, Kerr J, et al. Pharmacological treatment for mental health illnesses in adults receiving dialysis: A scoping review. Fundamental & Clinical Pharmacology. 2024;38(5):862-882. doi:10.1111/fcp.13022

BibTeX
@article{Wichart2024,
  author = {Wichart, Jenny and Yoeun, Peter and Chin, Tracy and Evernden, Christopher and Berendonk, Charlotte and Kerr, Jodi and Birchall, Alexandra and Boschee, Belinda and Defoe, Kimberly and Dhaliwal, Jasleen and KarisAllen, Tasia and Kennedy, Megan and McDonald, Alexis and Mierzejewski, Monika K and Schick-Makaroff, Kara},
  title = {Pharmacological treatment for mental health illnesses in adults receiving dialysis: A scoping review},
  journal = {Fundamental & Clinical Pharmacology},
  year = {2024},
  volume = {38},
  number = {5},
  pages = {862--882},
  doi = {10.1111/fcp.13022}
}
Kostenlos starten →